Skip to content
    Clinical Trials

    First-Line Anlotinib vs Bevacizumab Plus CapeOX in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

    Liu et alSignal Transduction and Targeted Therapy

    First-Line Anlotinib vs Bevacizumab Plus CapeOX in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
    The multicenter, prospective, randomized, open-label phase 3 ANCHOR trial evaluated first-line oral multitargeted TKI anlotinib versus bevacizumab, both combined with oxaliplatin and capecitabine (CapeOX), in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer (mCRC). A total of 748 patients were centrally randomized (1:1) to receive 4–8 cycles of CapeOX alongside either anlotinib (12 mg once daily on days 1–14; n = 373) or bevacizumab (7.5 mg/kg on day 1; n = 375) every 3 weeks, followed by maintenance therapy until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee, with a noninferiority hazard ratio (HR) margin set at 1.09.
    At a median follow-up of 25.1 months, median PFS was 11.0 months (95% CI 9.8–11.2) in the anlotinib group versus 11.0 months (95% CI 9.7–11.2) in the bevacizumab group (stratified HR 1.00; 95% CI 0.84–1.18; p = 0.87). Although both arms demonstrated similar overall antitumor activity, anlotinib plus CapeOX failed to meet the predefined noninferiority threshold for PFS due to the upper bound of the confidence interval exceeding 1.09. Furthermore, grade ≥3 treatment-related adverse events were more frequent in the anlotinib arm (64.9%) than in the bevacizumab arm (44.8%).

    Key Takeaways

    • First-line anlotinib plus CapeOX achieved a median progression-free survival of 11.0 months compared with 11.0 months for bevacizumab plus CapeOX (HR 1.00, 95% CI 0.84–1.18, p = 0.87), failing to meet the prespecified noninferiority margin HR threshold of 1.09.
    • Grade ≥3 treatment-related adverse events occurred in 64.9% of patients in the anlotinib group compared to 44.8% of patients in the bevacizumab group.
    Read the original sourceSignal Transduction and Targeted Therapy